Realcan Pharmaceutical Group Co (SZSE:002589) Risk Assessment

View and export this data going back to 2011. Start your Free Trial

What is Realcan Pharmaceutical Group Co Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Realcan Pharmaceutical Group Co is: High Risk: High uncertainty with risk-return tradeoff.

Competitive Comparison of Realcan Pharmaceutical Group Co's Risk Assessment

For the Medical Distribution subindustry, Realcan Pharmaceutical Group Co's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Realcan Pharmaceutical Group Co's Risk Assessment Distribution in the Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Realcan Pharmaceutical Group Co's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Realcan Pharmaceutical Group Co's Risk Assessment falls into.

Realcan Pharmaceutical Group Co (SZSE:002589) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Realcan Pharmaceutical Group Co Risk Assessment Related Terms

Thank you for viewing the detailed overview of Realcan Pharmaceutical Group Co's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Realcan Pharmaceutical Group Co (SZSE:002589) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Realcan Pharmaceutical Group Co Ltd (SZSE:002589) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 326, Airport Road, Zhifu District, Shandong Province, Yantai, CHN, 264004

Website

http://www.realcan.cn

Realcan Pharmaceutical Group Co Ltd is a Chinese company engaged in direct pharmaceuticals distribution services. The company's main business is divided into the Drug, vaccine, medical device circulation service; Medical industry third-party logistics; Medical information service; Medical logistics service; Chinese medicine plate; Hospital management sector; Medical industry research and development production sector; and Medical industry financial sector.

Executives

Zhang Ren Hua	Directors, executives
Han Xu	Director
Zhou Yun	Directors, Directors, and Executives
Wu Di	Executives
Su Li Chen	Executives
Wu Li Yan	Director
Tao Chun Fang	Supervisors
Han Song	Executives

Realcan Pharmaceutical Group Co (SZSE:002589) Headlines

No Headlines